Myeloablative BU, fludarabine, antithymocyte globulin and low-dose TBI in the treatment of juvenile myelomonocytic leukaemia with allogeneic haematopoietic cell transplantation

被引：0
|
作者：
G M T Guilcher
R Moorjani
T H Truong
V A Lewis
机构：
[1] University of Calgary,
[2] Section of Haematology/Oncology/Transplant,undefined
[3] Alberta Children’s Hospital,undefined
来源：
Bone Marrow Transplantation | 2015年 / 50卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：455 / 456
页数：1
相关论文
共 50 条
  • [1] Myeloablative BU, fludarabine, antithymocyte globulin and low-dose TBI in the treatment of juvenile myelomonocytic leukaemia with allogeneic haematopoietic cell transplantation
    Guilcher, G. M. T.
    Moorjani, R.
    Truong, T. H.
    Lewis, V. A.
    BONE MARROW TRANSPLANTATION, 2015, 50 (03) : 455 - 456
  • [2] Acute graft versus host disease after non-myeloablative allogeneic stem cell transplantation (NST) with low-dose TBI, fludarabine and antithymocyte globulin (ATG)
    Grosskreutz, CL
    Scigliano, E
    Fruchtman, SM
    Isola, LM
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 42 - 42
  • [3] Fludarabine, low-dose busulfan and antithymocyte globulin compared to fludarabine and low-dose TBI for reduced-intensity conditioning prior to allogeneic stem cell transplantation in patients with lymphoid malignancies
    Malard, F.
    Brissot, E.
    Guillaume, T.
    Chevallier, P.
    Delaunay, J.
    Ayari, S.
    Mahe, B.
    Dubruille, V.
    Blin, N.
    Gastinne, T.
    Harousseau, J. -L.
    Milpied, N.
    Le Gouill, S.
    Moreau, P.
    Mohty, M.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S290 - S291
  • [4] Reduced-intensity conditioning using fludarabine with either antithymocyte globulin and BU, or low-dose TBI allowing allogeneic hematopoietic SCT
    Cable, C.
    Buzzeo, M. P.
    Schold, J. D.
    Khan, S.
    Leather, H.
    Moreb, J.
    Jamieson, K.
    Scornik, J.
    Amdur, R. J.
    Wingard, J. R.
    Reddy, V.
    BONE MARROW TRANSPLANTATION, 2010, 45 (01) : 31 - 37
  • [5] Reduced-intensity conditioning using fludarabine with either antithymocyte globulin and BU, or low-dose TBI allowing allogeneic hematopoietic SCT
    C Cable
    M P Buzzeo
    J D Schold
    S Khan
    H Leather
    J Moreb
    K Jamieson
    J Scornik
    R J Amdur
    J R Wingard
    V Reddy
    Bone Marrow Transplantation, 2010, 45 : 31 - 37
  • [6] BUSULFAN, FLUDARABINE, ANTI-THYMOCYTE GLOBULIN AND LOW-DOSE TOTAL BODY IRRADIATION IN THE TREATMENT OF JUVENILE MYELOMONOCYTIC LEUKEMIA WITH MYELOABLATIVE STEM CELL TRANSPLANTATION
    Moorjani, R.
    Truong, T. H.
    Lewis, V.
    Guilcher, G. M. T.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S104 - S105
  • [7] Acute graft versus host disease after nonmyeloablative allogeneic stem cell transplantation with low-dose TBI, fludarabine and antithymocyte globulin (ATG).
    Grosskreutz, CL
    Egan, R
    Scigliano, E
    Fruchtman, SM
    Isola, LM
    BLOOD, 2004, 104 (11) : 354A - 354A
  • [8] Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation
    Grosskreutz, C
    Ross, V
    Scigliano, E
    Fruchtman, S
    Isola, L
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (07) : 453 - 459
  • [9] The influence of adding low-dose (400cGy) total body irradiation (TBI) on outcomes of allogeneic stem cell transplantation for acute myelogenous leukaemia (AML) with myeloablative conditioning incorporating daily intravenous busulfan, fludarabine and low-dose antithymocyte globulin.
    Savoie, ML
    Balogh, A
    Chaudhry, MA
    Jeje, O
    Stewart, DA
    Bahlis, NJ
    Storek, J
    Brown, CB
    Quinlan, DM
    Turner, AR
    Larratt, LM
    Russell, JA
    BLOOD, 2005, 106 (11) : 767A - 767A
  • [10] Reduced-intensity conditioning with fludarabine, low-dose busulfan and antithymocyte globulin prior to allogeneic stem cell transplantation
    Malard, F.
    Brissot, E.
    Delaunay, J.
    Ayari, S.
    Guillaume, T.
    Chevallier, P.
    Dubruille, V.
    Mahe, B.
    Blin, N.
    Gastinne, T.
    Le Gouill, S.
    Saulquin, B.
    Harousseau, J. L.
    Moreau, P.
    Milpied, N.
    Mohty, M.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S290 - S290
12345